Absence of novel human parvovirus (PARV4) in Danish mothers and children

Linstow, Marie‐Louise von; Rosenfeldt, Vibeke; Lindberg, Ellinor; Jensen, Lise; Hedman, Lea; Li, Xuemeng; Väisänen, Elina; Hedman, Klaus; Norja, Päivi

doi:10.1016/j.jcv.2015.01.021

Cited by 7 publications

(5 citation statements)

References 28 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher positivity in children less than 5 years of age and during winter is demonstrable with the current data. Most of the studies have commented on positivity in children; however, seasonality is not well described (Panning et al, 2010;Rosenfeldt et al, 2015;von Linstow et al, 2015). Co-infection with other respiratory viruses is also seen in the present study.…”

Section: Discussioncontrasting

confidence: 64%

Human Parvovirus 4: A harmless bystander or a pathogen of severe acute respiratory illness

Prakash

Shukla

Ramakrishna

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Introduction: Severe Acute Respiratory Infection (SARI) is an important cause of morbidity and mortality worldwide, caused by a large number of viral and bacterial agents. PARV4 is a recently identified virus detected in human blood and variety of tissues, but its disease association with SARI could not be established.Objective: In the present case control study, we aim to investigate the association of PARV4 with SARI. Methods: The Nasal and Throat swab (NS/TS) samples of 241 cases and 146 healthy controls were tested for most common respiratory viruses and PARV4 by real-time PCR. Results: PARV4 was detected in 64(26.55%) SARI cases and only one healthy control (0.68%). PARV4 was the most common viral agent detected in SARI cases. A strong association of PARV4 is seen with severe respiratory illness. Conclusion: Detection of PARV4 in a significantly higher number of SARI cases, in comparison with controls, suggests association of PARV4 with SARI. PARV4 genotype 2 is the only circulating strain detected in our study.

show abstract

Section: Discussioncontrasting

confidence: 64%

Human Parvovirus 4: A harmless bystander or a pathogen of severe acute respiratory illness

Prakash

Shukla

Ramakrishna

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…However, in this study, the background prevalence of viraemia in healthy blood donors was also high at 17% 19 . Higher seroprevalence was also reported in Scandinavian subjects in the setting of HIV infection; the PARV4 IgG detection frequency was 8% among HIV-positive children 17 , while the background population seropositivity rate was less than 1% in adults and absent in children 18 , 22 . Stratification of risk factors in a French study reported the highest PARV4 prevalence in PWIDs, especially among those who were HIV-infected, but also among men who have sex with men (MSM), particularly those likely to have been exposed in the 1980s 12 .…”

Section: New Advances In the Parv4 Literaturementioning

confidence: 70%

“…The most substantial updates to the PARV4 literature are studies to determine the prevalence of infection in geographic areas that had not previously been represented. This includes new studies in Scandinavia 17 , 18 , the Middle East 19 , and South America 20 , 21 ; we have summarised these data in Table 2 . Below, we discuss these findings with further reference to their applicability to understanding risk factors for infection.…”

Section: New Advances In the Parv4 Literaturementioning

confidence: 99%

Human parvovirus 4 ‘PARV4’ remains elusive despite a decade of study

2017

View full text Add to dashboard Cite

Human parvovirus 4 (‘PARV4’) is a small DNA tetraparvovirus, first reported in 2005. In some populations, PARV4 infection is uncommon, and evidence of exposure is found only in individuals with risk factors for parenteral infection who are infected with other blood-borne viruses. In other settings, seroprevalence studies suggest an endemic, age-associated transmission pattern, independent of any specific risk factors. The clinical impact of PARV4 infection remains uncertain, but reported disease associations include an influenza-like syndrome, encephalitis, acceleration of HIV disease, and foetal hydrops. In this review, we set out to report progress updates from the recent literature, focusing on the investigation of cohorts in different geographical settings, now including insights from Asia, the Middle East, and South America, and discussing whether attributes of viral or host populations underpin the striking differences in epidemiology. We review progress in understanding viral phylogeny and biology, approaches to diagnostics, and insights that might be gained from studies of closely related animal pathogens. Crucial questions about pathogenicity remain unanswered, but we highlight new evidence supporting a possible link between PARV4 and an encephalitis syndrome. The unequivocal evidence that PARV4 is endemic in certain populations should drive ongoing research efforts to understand risk factors and routes of transmission and to gain new insights into the impact of this virus on human health.

show abstract

“…PARV4 VP2-generated VLPs have been used to establish an IgG EIA and a -captureformat IgM EIA for serodiagnosis (325,1154,1157). In the general population, the seroprevalence of PARV4 varies by genotype and geographically, from 20 to 37% in sub-Saharan Africa (1168) to 9.4% for a low-risk population in Lithuania (1169), 4.76% for blood donors in the United Kingdom (1170), and 0% in healthy subjects in Nordic countries (1154,1171). Additionally, PARV4 infection induced strong, broad, and persistent T cell responses (1164).…”

Section: Other Emerging Human Parvoviruses Human Parvovirusmentioning

confidence: 99%

Human Parvoviruses

2017

View full text Add to dashboard Cite

Parvovirus B19 (B19V) and human bocavirus 1 (HBoV1), members of the large Parvoviridae family, are human pathogens responsible for a variety of diseases. For B19V in particular, host features determine disease manifestations. These viruses are prevalent worldwide and are culturable in vitro, and serological and molecular assays are available but require careful interpretation of results. Additional human parvoviruses, including HBoV2 to -4, human parvovirus 4 (PARV4), and human bufavirus (BuV) are also reviewed. The full spectrum of parvovirus disease in humans has yet to be established. Candidate recombinant B19V vaccines have been developed but may not be commercially feasible. We review relevant features of the molecular and cellular biology of these viruses, and the human immune response that they elicit, which have allowed a deep understanding of pathophysiology.

show abstract

Absence of novel human parvovirus (PARV4) in Danish mothers and children

Cited by 7 publications

References 28 publications

Human Parvovirus 4: A harmless bystander or a pathogen of severe acute respiratory illness

Human Parvovirus 4: A harmless bystander or a pathogen of severe acute respiratory illness

Human parvovirus 4 ‘PARV4’ remains elusive despite a decade of study

Human Parvoviruses

Contact Info

Product

Resources

About